James Abbruzzese, MD

Professor of Medicine
D. C. I. Distinguished Professor of Medical Oncology
Chief, Division of Medical Oncology
Member of the Duke Cancer Institute
Campus mail 440 Mudd Building, Box 3406, Durham, NC 27710
Email address james.abbruzzese@duke.edu

My research interests include the clinical study and treatment of pancreatic cancer.

In Their Words

Education and Training

  • Resident, Internal Medicine, Johns Hopkins University School of Medicine, 1979 - 1981
  • Intern, Internal Medicine, Johns Hopkins University School of Medicine, 1978 - 1979
  • M.D., The University of Chicago, 1978

Publications

Nixon, Andrew, Joyce Liu, Niya Xiong, Herbert I. Hurwitz, Jing Lyu, Yingmiao Liu, Mark Starr, et al. “Blood-based biomarkers in patients with platinum-sensitive and resistant ovarian cancer treated with olaparib and cediranib: results from the UM9825 trial.” In Gynecologic Oncology, 162:S99–S99, 2021.

Scholars@Duke

Subbiah, Vivek, Mark M. Awad, Adil Daud, Martin Gutierrez, Jessica Dreger McDermott, Sai-Hong Ignatius Ou, Tomoko Hirohashi, et al. “Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors.” In Journal of Clinical Oncology, 39:TPS2671–TPS2671. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.tps2671.

Full Text

Moschos, Stergios J., Zeynep Eroglu, Nikhil I. Khushalani, Kari L. Kendra, George Ansstas, Gino K. In, Peng Wang, et al. “Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922).” Melanoma Res 31, no. 2 (April 1, 2021): 162–72. https://doi.org/10.1097/CMR.0000000000000726.

PMID
33661190
Full Text

Liu, Muyun, Dan Wang, Yongde Luo, Lianghao Hu, Yawei Bi, Juntao Ji, Haojie Huang, et al. “Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesis.” Cell Death Dis 12, no. 2 (February 16, 2021): 189. https://doi.org/10.1038/s41419-021-03473-6.

PMID
33594044
Full Text

Luo, Yongde, Xiaokun Li, Jianjia Ma, James L. Abbruzzese, and Weiqin Lu. “Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity.” Cancers (Basel) 13, no. 4 (February 13, 2021). https://doi.org/10.3390/cancers13040778.

PMID
33668583
Full Text

DeVito, Nicholas C., Colm Kelleher, Kyle C. Strickland, James Abbruzzese, Carey Anders, Brent A. Hanks, Jingquan Jia, et al. “A case report of microsatellite instability (MSI)-high, HER2 amplified pancreatic adenocarcinoma with central nervous system metastasis.” Ame Case Reports 5 (January 2021): 14. https://doi.org/10.21037/acr-20-154.

PMID
33912803
Full Text

Green, Michelle F., Jonathan L. Bell, Christopher B. Hubbard, Shannon J. McCall, Matthew S. McKinney, Jinny E. Riedel, Carolyn S. Menendez, James L. Abbruzzese, John H. Strickler, and Michael B. Datto. “Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience.” Jco Precis Oncol 5 (2021). https://doi.org/10.1200/PO.21.00030.

PMID
34568718
Full Text

Turner, Megan C., Sabran J. Masoud, Marcelo Cerullo, Mohamed A. Adam, Kevin N. Shah, Dan G. Blazer, James L. Abbruzzese, and Sabino Zani. “Improved overall survival is still observed in patients receiving delayed adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.” Hpb (Oxford) 22, no. 11 (November 2020): 1542–48. https://doi.org/10.1016/j.hpb.2020.03.006.

PMID
32299656
Full Text

Liu, Xiaowen, Danwen Qian, Hongliang Liu, James L. Abbruzzese, Sheng Luo, Kyle M. Walsh, and Qingyi Wei. “Genetic variants of the peroxisome proliferator-activated receptor (PPAR) signaling pathway genes and risk of pancreatic cancer.” Mol Carcinog 59, no. 8 (August 2020): 930–39. https://doi.org/10.1002/mc.23208.

PMID
32367578
Full Text

Liu, Joyce F., Su-Chun Cheng, Robert M. Wenham, Andrea E Wahner Hendrickson, Deborah K. Armstrong, Nancy Chan, David E. Cohn, et al. “Abstract A074: Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer.” In Clinical Trials. American Association for Cancer Research, 2019. https://doi.org/10.1158/1535-7163.targ-19-a074.

Full Text

Pages